An Integrated Nanotechnology-Enabled Transbronchial Image-Guided Intervention Strategy for Peripheral Lung Cancer

• Published in: Cancer research (Chicago, Ill.) Vol. 76; no. 19; pp. 5870 - 5880
• Main Authors: Jin, Cheng S., Wada, Hironobu, Anayama, Takashi, McVeigh, Patrick Z., Hu, Hsin Pei, Hirohashi, Kentaro, Nakajima, Takahiro, Kato, Tatsuya, Keshavjee, Shaf, Hwang, David, Wilson, Brian C., Zheng, Gang, Yasufuku, Kazuhiro
• Format: Journal Article
• Language: English
• Published: United States 01.10.2016
• Subjects: Animals; Bronchoscopy; Fluorescence; Humans; Low-Level Light Therapy; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - therapy; Mice; Nanoparticles - administration & dosage; Neoplasm Transplantation; Phantoms, Imaging; Rabbits; Transplantation, Heterologous
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-15-3196

Early detection and efficient treatment modality of early-stage peripheral lung cancer is essential. Current nonsurgical treatments for peripheral lung cancer show critical limitations associated with various complications, requiring alternative minimally invasive therapeutics. Porphysome nanoparticle-enabled fluorescence-guided transbronchial photothermal therapy (PTT) of peripheral lung cancer was developed and demonstrated in preclinical animal models. Systemically administered porphysomes accumulated in lung tumors with significantly enhanced disease-to-normal tissue contrast, as confirmed in three subtypes of orthotopic human lung cancer xenografts (A549, H460, and H520) in mice and in an orthotopic VX2 tumor in rabbits. An in-house prototype fluorescence bronchoscope demonstrated the capability of porphysomes for in vivo imaging of lung tumors in the mucosal/submucosal layers, providing real-time fluorescence guidance for transbronchial PTT. Porphysomes also enhanced the efficacy of transbronchial PTT significantly and resulted in selective and efficient tumor tissue ablation in the rabbit model. A clinically used cylindrical diffuser fiber successfully achieved tumor-specific thermal ablation, showing promising evidence for the clinical translation of this novel platform to impact upon nonsurgical treatment of early-stage peripheral lung cancer. Cancer Res; 76(19); 5870–80. ©2016 AACR.